Femasys Inc (FEMY)

$0.63 +0.02 (3.50%)
Market Cap 19.83M
Revenue (ttm) 1.63M
Net Income (ttm) -18.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,154.60%
Debt to Equity Ratio 0.07
Volume 12,363,101
Avg Vol 7,032,468
Day's Range N/A - N/A
Shares Out 32.58M
Stochastic %K 30%
Beta -2.64
Analysts Strong Sell
Price Target $6.25

Company Profile

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination solution; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; FemCath, a cornual balloon catheter for selective fallopian tube evaluation; and FemChec, a controlled contrast-genera...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 770 500 3910
Fax: 404 581 5903
Address:
3950 Johns Creek Court, Suite 100, Suwanee, United States
goldenxb
goldenxb Oct. 25 at 12:59 PM
$FEMY
0 · Reply
SuperErica
SuperErica Oct. 25 at 1:41 AM
$EEIQ $1+Next week, Don't miss this gap up, pretty low risk play as its sitting near 52 weeks low, high upside potential as pennies continues to be hot. $FEMY $ARTV $ZOOZ
0 · Reply
Drlee5647
Drlee5647 Oct. 24 at 10:58 PM
$FEMY what are total turd
0 · Reply
Toptradersam
Toptradersam Oct. 24 at 8:01 PM
$AI $ARTV $NEUP $FEMY Watchlists breakdown! 🔥 https://www.youtube.com/watch?v=chPJhJh4JpM
0 · Reply
stoneblood
stoneblood Oct. 24 at 8:00 PM
$FEMY not a bad close imho missed the bottom by a couple pennies today from a technical standpoint i am very pleased we didnt print a massive gap on the daily
0 · Reply
JamboFC85
JamboFC85 Oct. 24 at 7:51 PM
$FEMY so what does the sentiment mean and what does messages mean when reading the chart?
0 · Reply
MrN69
MrN69 Oct. 24 at 7:26 PM
$FEMY would be nice if there closed around 0.70
0 · Reply
Nukister
Nukister Oct. 24 at 7:10 PM
$FEMY Where you going FEMY, are you in a hurry?
1 · Reply
4RiskyBusiness4
4RiskyBusiness4 Oct. 24 at 7:09 PM
$FEMY Crossed the threshold. Potential for continuance…
0 · Reply
TripTrap
TripTrap Oct. 24 at 7:05 PM
$FEMY Elevator going back up...
0 · Reply
Latest News on FEMY
Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo

Oct 16, 2025, 9:00 AM EDT - 9 days ago

Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo

Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®

Sep 11, 2025, 9:00 AM EDT - 6 weeks ago

Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®

Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand

Sep 8, 2025, 9:00 AM EDT - 6 weeks ago

Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand

Femasys Announces Pricing of $8.0 Million Underwritten Public Offering

Aug 25, 2025, 11:44 PM EDT - 2 months ago

Femasys Announces Pricing of $8.0 Million Underwritten Public Offering

Femasys Announces Second Quarter Financial Results for 2025

Aug 8, 2025, 4:05 PM EDT - 2 months ago

Femasys Announces Second Quarter Financial Results for 2025

Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion

Aug 6, 2025, 9:00 AM EDT - 2 months ago

Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion

Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic

Jul 1, 2025, 9:00 AM EDT - 4 months ago

Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic

Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control

Jun 25, 2025, 9:00 AM EDT - 4 months ago

Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control

Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

Jun 17, 2025, 9:00 AM EDT - 4 months ago

Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

Femasys Announces Partnership with Carolinas Fertility Institute, One of America's Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations

Jun 11, 2025, 9:00 AM EDT - 4 months ago

Femasys Announces Partnership with Carolinas Fertility Institute, One of America's Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations

Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

May 29, 2025, 4:23 PM EDT - 5 months ago

Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

May 8, 2025, 5:01 PM EDT - 6 months ago

Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

Mar 27, 2025, 9:00 AM EDT - 7 months ago

Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations

Mar 19, 2025, 9:20 AM EDT - 7 months ago

Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations

Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain

Mar 18, 2025, 9:00 AM EDT - 7 months ago

Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain

Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach

Mar 13, 2025, 8:30 AM EDT - 8 months ago

Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach

Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials

Feb 25, 2025, 9:20 AM EST - 8 months ago

Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials

Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices

Feb 11, 2025, 9:00 AM EST - 9 months ago

Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices

Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control

Jan 30, 2025, 8:30 AM EST - 9 months ago

Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control

Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment

Jan 16, 2025, 8:30 AM EST - 10 months ago

Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment

Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment

Nov 26, 2024, 8:30 AM EST - 11 months ago

Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment

Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

Nov 12, 2024, 8:30 AM EST - 1 year ago

Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control

Nov 1, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control

Femasys to Exhibit at ASRM 2024 and Participate in the Congress' KEEPR Education Program

Oct 10, 2024, 8:30 AM EDT - 1 year ago

Femasys to Exhibit at ASRM 2024 and Participate in the Congress' KEEPR Education Program

Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments

Oct 2, 2024, 8:30 AM EDT - 1 year ago

Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments

Femasys Announces Infertility Clinic Customers from Coast to Coast

Sep 18, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Infertility Clinic Customers from Coast to Coast

Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market

Sep 11, 2024, 8:30 AM EDT - 1 year ago

Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market

Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check

Sep 9, 2024, 8:30 AM EDT - 1 year ago

Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check

Femasys to Exhibit at The Canadian Fertility and Andrology Society's 70th Annual Meeting

Sep 5, 2024, 8:30 AM EDT - 1 year ago

Femasys to Exhibit at The Canadian Fertility and Andrology Society's 70th Annual Meeting

Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution

Aug 29, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution

Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters

Aug 27, 2024, 8:30 AM EDT - 1 year ago

Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters

Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update

Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam

Jun 27, 2024, 8:30 AM EDT - 1 year ago

Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative

May 17, 2024, 8:30 AM EDT - 1 year ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Gender Policy Council

May 16, 2024, 8:30 AM EDT - 1 year ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Gender Policy Council

Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update

May 9, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update

Femasys Expands Commercial Management Team with Addition of Experienced New Hires

May 7, 2024, 8:30 AM EDT - 1 year ago

Femasys Expands Commercial Management Team with Addition of Experienced New Hires

Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare Initiatives

Apr 18, 2024, 8:30 AM EDT - 1 year ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare Initiatives

Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update

Mar 28, 2024, 4:05 PM EDT - 1 year ago

Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update

Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

Mar 21, 2024, 9:00 AM EDT - 1 year ago

Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility

Mar 20, 2024, 8:15 AM EDT - 1 year ago

Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution

Mar 6, 2024, 9:00 AM EST - 1 year ago

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution

Femasys' FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF

Feb 28, 2024, 9:00 AM EST - 1 year ago

Femasys' FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF

Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer

Feb 6, 2024, 8:30 AM EST - 1 year ago

Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women

Jan 26, 2024, 8:00 AM EST - 1 year ago

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology

Jan 23, 2024, 8:30 AM EST - 1 year ago

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine

Dec 15, 2023, 8:30 AM EST - 2 years ago

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine

Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer

Nov 30, 2023, 8:30 AM EST - 2 years ago

Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer

Femasys: A Women's Health Medical Devices Company Ready To Turn The Corner

Nov 28, 2023, 8:40 AM EST - 2 years ago

Femasys: A Women's Health Medical Devices Company Ready To Turn The Corner

goldenxb
goldenxb Oct. 25 at 12:59 PM
$FEMY
0 · Reply
SuperErica
SuperErica Oct. 25 at 1:41 AM
$EEIQ $1+Next week, Don't miss this gap up, pretty low risk play as its sitting near 52 weeks low, high upside potential as pennies continues to be hot. $FEMY $ARTV $ZOOZ
0 · Reply
Drlee5647
Drlee5647 Oct. 24 at 10:58 PM
$FEMY what are total turd
0 · Reply
Toptradersam
Toptradersam Oct. 24 at 8:01 PM
$AI $ARTV $NEUP $FEMY Watchlists breakdown! 🔥 https://www.youtube.com/watch?v=chPJhJh4JpM
0 · Reply
stoneblood
stoneblood Oct. 24 at 8:00 PM
$FEMY not a bad close imho missed the bottom by a couple pennies today from a technical standpoint i am very pleased we didnt print a massive gap on the daily
0 · Reply
JamboFC85
JamboFC85 Oct. 24 at 7:51 PM
$FEMY so what does the sentiment mean and what does messages mean when reading the chart?
0 · Reply
MrN69
MrN69 Oct. 24 at 7:26 PM
$FEMY would be nice if there closed around 0.70
0 · Reply
Nukister
Nukister Oct. 24 at 7:10 PM
$FEMY Where you going FEMY, are you in a hurry?
1 · Reply
4RiskyBusiness4
4RiskyBusiness4 Oct. 24 at 7:09 PM
$FEMY Crossed the threshold. Potential for continuance…
0 · Reply
TripTrap
TripTrap Oct. 24 at 7:05 PM
$FEMY Elevator going back up...
0 · Reply
trad3r3r
trad3r3r Oct. 24 at 6:45 PM
$FEMY AH squeeze
0 · Reply
MrN69
MrN69 Oct. 24 at 6:38 PM
$FEMY what a beautiful dip
1 · Reply
JohnnyUtah309
JohnnyUtah309 Oct. 24 at 6:37 PM
$FEMY off we go!!
0 · Reply
thegoodcall
thegoodcall Oct. 24 at 6:34 PM
$PRZO $PRZO keep your eyes on it. Big run can happen AH $BURU $WGRX $FEMY $AIIO
1 · Reply
ontheflop
ontheflop Oct. 24 at 6:27 PM
$FEMY
0 · Reply
rrc2007
rrc2007 Oct. 24 at 6:08 PM
$FEMY
0 · Reply
DoyleStockkks
DoyleStockkks Oct. 24 at 5:55 PM
$FEMY What's with the high volume and no spike? Everything looks like this stock will continue to grow well.
1 · Reply
bilocelhi
bilocelhi Oct. 24 at 5:18 PM
$FEMY possible short, on watch
1 · Reply
Trissy08
Trissy08 Oct. 24 at 4:43 PM
$FEMY hmmmmm not great movements today. I’m done with the .50 and .60 levels. Be gone with you.
0 · Reply
QQuant
QQuant Oct. 24 at 4:30 PM
$FEMY - I will be still sticking to my previous prediction as there two more catalysts left on the fundamentals side of the FEMY. - Trumps speech over the weekend regarding fertilisation. - Nov 5th earnings report. This stock has the correct instruments to be very bullish due to the fundamentals indicators and the technical indicators and might be go to the land of the double digits. I will continue to buy when big dips happen.
2 · Reply
Peter1735
Peter1735 Oct. 24 at 4:29 PM
$FEMY every posts today look bullish and this garbage keeps dipping
1 · Reply
onions86
onions86 Oct. 24 at 4:19 PM
$FEMY feels like something big is coming
0 · Reply